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Abstract
Purpose Conventional chemotherapy has limited activity
in patients with breast cancer and brain metastases
(BCBM). Etirinotecan pegol (EP), a novel long-acting
topoisomerase-1 inhibitor, was designed using advanced
polymer technology to preferentially accumulate in tumor
tissue including brain metastases, providing sustained
cytotoxic SN38 levels.
Methods The phase 3 BEACON trial enrolled 852 women
with heavily pretreated locally recurrent or metastatic
breast cancer between 2011 and 2013. BEACON compared
EP with treatment of physician’s choice (TPC; eribulin,
vinorelbine, gemcitabine, nab-paclitaxel, paclitaxel,
ixabepilone, or docetaxel) in patients previously treated
with anthracycline, taxane, and capecitabine, including
those with treated, stable brain metastases. The primary
endpoint, overall survival (OS), was assessed in a pre-de-
fined subgroup of BCBM patients; an exploratory post hoc
analysis adjusting for the diagnosis-specific graded prog-
nostic assessment (GPA) index was also conducted.
Results In the trial, 67 BCBM patients were randomized
(EP, n = 36; TPC, n = 31). Treatment subgroups were
balanced for baseline characteristics and GPA indices. EP
was associated with a significant reduction in the risk of
death (HR 0.51; P\ 0.01) versus TPC; median OS was
10.0 and 4.8 months, respectively. Improvement in OS was
observed in both poorer and better GPA prognostic groups.
Survival rates at 12 months were 44.4% for EP versus
19.4% for TPC. Consistent with the overall BEACON
population, fewer patients on EP experienced grade C3
toxicity (50 vs. 70%).
Conclusions The significant improvement in survival in
BCBM patients provides encouraging data for EP in thisElectronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4304-7) contains supplementary
material, which is available to authorized users.
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difficult-to-treat subgroup of patients. A phase three trial of
EP in BCBM patients is underway (ClinicalTrials.gov
NCT02915744).
Keywords Brain metastases  Etirinotecan pegol  NKTR-
102  Chemotherapy  Metastatic breast cancer
Abbreviations
AE Adverse events
BC Breast cancer
BCBM Breast cancer and brain metastases
BEACON BrEAst cancer outcomes with NKTR-102
BM Brain metastases
BMH History of treated, stable breast cancer brain
metastases
CI Confidence interval
CNS Central nervous system
CTCAE Common toxicity criteria for adverse events,
version 4.0
ECOG Eastern Cooperative Oncology Group
EP Etirinotecan pegol
ER Estrogen receptor
GBM Glioblastoma multiforme
GPA Graded prognostic assessment
HER2 Human epidermal growth factor receptor 2
HR Hazard ratio
ITT Intention-to-treat
KM Kaplan–Meier
KPS Karnofsky performance score
LR Locally recurrent
MBC Metastatic breast cancer
MMRM Repeated measure linear mixed model
NCI National Cancer Institute
ORR Objective response rate
OS Overall survival
PD Progressive disease
PFS Progression-free survival
PR Progesterone receptor
PS Performance status
RECIST Response evaluation criteria in solid tumors
RT Radiation therapy
TPC Treatment of physician’s choice
Introduction
The rising incidence of brain metastases (BM) as a late
manifestation of advanced malignancies is a major clin-
ical problem [1–8], with a prevalence in unselected
patients with metastatic breast cancer (MBC) reaching as
high as 30% [2]. Depending on the breast cancer sub-
type, the vast majority of patients who develop BM have
synchronous extra-cranial disease; consequently, effective
therapeutic strategies must control intra-cranial and extra-
cranial disease while maintaining or improving patients’
quality of life (QoL) [7, 8]. Indeed, in patients with
breast cancer and BM (BCBM), control of systemic
disease is strongly associated with improved outcomes
[9–11]. Treatment options for patients with BCBM,
whether de novo, recurrent following prior local surgery
and/or radiotherapy, or progressive disease on radiother-
apy are dismal, with small prospective trials showing
modest response rates and short palliative benefit
[5, 11–15].
No cytotoxic or molecularly targeted agent is approved
for the treatment or prevention of BCBM [11, 12].
Molecular weight, lipophilicity, biodistribution, and drug
efflux pumps all contribute to poor penetration of drugs
through the blood–brain barrier and into the brain [16],
although extent to which therapeutic resistance relates to
inadequate drug penetration remains unclear, as does the
degree to which the blood–tumor barrier is disrupted
[11, 12, 15]. Current therapies have limited activity in
patients with BCBM, especially those recurring post-ra-
diation therapy [5, 11–14, 17]. This is particularly
important for patients with triple-negative breast cancer
(TNBC), who have a high incidence of BM and for whom
there are currently no approved targeted therapies
[9, 18–20].
Etirinotecan pegol (EP) is a novel long-acting topoi-
somerase-1 inhibitor designed to improve safety and
efficacy of irinotecan by generating lower peak plasma
concentrations, significantly extending the effective half-
life of the SN38, the active moiety of irinotecan, from 2
to approximately 38 days [21], and concentrate deposition
of the parent drug within tumor tissue. Using an experi-
mental mouse model with established BM, a significant
reduction in both the number and size of established BM
and a 50% survival rate were reported for mice treated
with EP; surviving animals harbored only minimal
residual disease [21–23]. These findings support the
ability of EP to cross the blood–tumor barrier, leading to
preferential accumulation and retention in BM, followed
by sustained exposure to SN38 at concentrations leading
to cytotoxicity.
In the phase 3 BEACON (BrEAst Cancer Outcomes
with NKTR-102) trial, patients with heavily pretreated
MBC were randomized 1:1 to EP or single-agent treatment
of physician’s choice (TPC) [24]. The trial allowed inclu-
sion of patients with a history of treated, stable BM. To
assess the efficacy of EP in these patients, pre-specified
subgroup analyses of efficacy and safety were conducted
and are reported herein. In addition, we report a post hoc
analysis of survival stratified retrospectively according to
the validated breast cancer-specific Graded Prognostic
Assessment (GPA) index [25, 26].
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Materials and methods
Patients
Patients eligible for the BEACON study were women
(18 years or older) with an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 or 1; had
histologically or cytologically confirmed carcinoma of the
breast; measurable (by Response Evaluation Criteria in
Solid Tumors [RECIST] version 1.1) [27] or non-measur-
able disease; prior therapy (in neoadjuvant, adjuvant and/or
metastatic setting) with an anthracycline (unless not med-
ically appropriate or contraindicated), a taxane, and cape-
citabine; and received between 2 and 5 prior cytotoxic
regimens for locally recurrent and/or MBC, with the last
dose of cytotoxic chemotherapy within 6 months of ran-
domization. Patients with a history of BM were eligible
provided their BM were symptomatically and radiologi-
cally stable, local therapy (surgery, whole brain or stereo-
tactic radiation) had been completed, and corticosteroids
for this indication had been discontinued C3 weeks prior
to randomization. Signs and/or symptoms of BM had to
have been stable for C28 days prior to randomization.
Radiologic assessment of the brain at screening was
required in patients with focal neurological signs or known
BM. Patients with symptomatic or radiologic progression
(according to RECIST v1.1) of BM at screening, lep-
tomeningeal disease, or meningeal carcinomatosis were
excluded.
Study design
The study design, methodology, and results for primary and
selected secondary endpoints have been previously repor-
ted [24]. A preplanned analysis was conducted in the
subgroup of patients with a history of treated, stable BM at
the time of study enrollment. The study was conducted
according to the Declaration of Helsinki and under the
principles of the International Conference on Harmoniza-
tion Good Clinical Practice standards. All patients provided
written informed consent, and the study was approved by
relevant institutional review board or independent ethics
committee.
Administration of study treatments
EP (145 mg/m2) was administered every 21 days as a
90-min infusion. TPC options were defined in the protocol
as single-agent eribulin, ixabepilone, vinorelbine, gemc-
itabine, paclitaxel, docetaxel, or nab-paclitaxel and
administered according to local practice, with the excep-
tion of eribulin and ixabepilone, which were administered
according to local product labeling. Prior to randomization,
the investigator selected and centrally registered the rele-
vant TPC agent.
Assessments
Radiological examination was required B28 days prior to
randomization and every 8 weeks (±7 days) thereafter
until progressive disease (PD) was noted. The same
imaging modality was required for subsequent radiographic
assessment, whether there was measurable or non-mea-
surable disease (RECIST v1.1). Adverse events (AEs) were
assessed from the first dose of treatment until 30 days after
the last dose and graded according to the National Cancer
Institute (NCI) Common Toxicity Criteria for Adverse
Events (CTCAE), version 4.0.
Statistical methodology
Based on a planned sample size of 840 patients (420
patients per treatment arm), the BEACON trial had 90%
power to detect a hazard ratio of 0.77 for overall survival
(OS) based on death from any cause, with a two-sided
alpha level of 0.049. Patients were stratified for geo-
graphical region, receptor subtype, and prior eribulin use
(patients were not stratified for a history of BM). Patients
with a history of treated, stable BM (BCBM subgroup)
were assessed for efficacy in terms of OS (time from ran-
domization to death from any cause), progression-free
survival (PFS; time to the earliest evidence of documented
disease progression as assessed by the investigator or death
from any cause), and systemic objective response rate
(ORR; proportion of patients with measurable disease at
baseline and a confirmed complete response, partial
response, stable disease, or PD by RECIST v1.1 criteria).
Kaplan–Meier (KM) estimates of survival were summa-
rized and displayed graphically; two-sided unstratified log-
rank tests were used to compare OS and PFS between
treatment groups. For OS (primary analysis), patients not
reported as having died at the time of the data cut-off were
censored at the date they were last known to be alive.
Hazard ratios (HR) for EP versus TPC and corresponding
95% confidence intervals (CI) were estimated using an
unstratified Cox regression model. All P-values reported
are exploratory; no adjustments were made for the
exploratory analyses in the BCBM subgroup.
Survival data were also evaluated in an exploratory post
hoc analysis using the GPA index [26]. To calculate GPA,
ECOG PS was converted to Karnofsky performance score
(KPS) (Table S1) and receptor status (human epidermal
growth factor receptor 2 [HER2], estrogen receptor, and
progesterone receptor) defined tumor subtype (HER2-pos-
itive, Basal, Luminal A, Luminal B) (Table S2). GPA
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scores range from 0 (worst prognosis) to 4 (best prognosis)
and grouped as 0–2.0 and 2.5–4.0. ORR was based on
investigator-assessed measurable disease at baseline; Fis-
cher’s exact test and Clopper–Pearson exact two-sided 95%
CI were calculated for each arm accordingly. The maxi-
mum NCI CTCAE grade and frequency of AEs were
compared between the BCBM treatment groups. AEs were
summarized for patients who received at least one study
drug dose. Odds ratios comparing EP versus TPC were
calculated for selected AEs occurring in C10% of patients.
Results
Of the 852 patients randomized in the BEACON trial at
135 medical centers between December 2011 and August
2013, 67 patients had a history of treated, stable BM (EP
arm, n = 36; TPC arm, n = 31). Of these, 19 patients
randomized to EP and 18 randomized to TPC had radio-
logically detectable BM at study entry. Of the 67 patients,
61 (91%; 34 out of 36 patients in EP and 27 out of 31
patients in TPC) had received prior radiotherapy to their
BM; 11 patients (16%) had undergone surgical resection,
most in combination with radiotherapy. Time from initial
BM diagnosis was similar between the two groups: 0.91
and 0.58 years for the EP and TPC groups, respectively.
Median time since last brain-directed radiotherapy to first
study treatment was also similar between the two groups:
7.8 and 6.7 months for the EP and TPC groups,
respectively.
As denoted in Table 1, BCBM patients had similar
patient and disease characteristics at baseline to those of
the overall BEACON intention-to-treat (ITT) population.
In BCBM patients, critical baseline prognostic features
were balanced between the two groups (including central
nervous system (CNS)-directed therapy, patients with
TNBC, median time since diagnosis of breast cancer and a
diagnosis of BM, and GPA score). Some marginal differ-
ences in baseline features observed baseline ECOG PS 0
(30.6% of patients in EP arm vs. 16.1% in TPC arm) and
liver involvement (72.2% vs. 58.1% in the EP and TPC
arms, respectively). The median number of days of study
drug exposure for patients in the BCBM population was
similar between treatment arms (47.5 days for EP and
44 days for TPC); both treatment arms received a median
number of three cycles. The maximum number of study
drug cycles was 23 for EP and 13 for TPC. Of the patients
receiving TPC, the majority received multiple (weekly)
infusions in each treatment cycle (four patients received a
single infusion every 3 weeks).
Efficacy
With a median follow-up of 21.1 months for the EP arm
and 21.7 months for the TPC arm in the primary survival
analysis, a total of 60 deaths occurred in the 67 BCBM
patients; 31 (86.1%) in the EP arm and 29 (93.5%) in the
TPC arm. Median OS was 10.0 months (95% CI
7.8–15.7 months) versus 4.8 months (95% CI
3.7–7.3 months) for patients randomized to EP and TPC,
respectively (Table 2); KM-curves are shown in Fig. 1,
demonstrating a HR of 0.51 (95% CI 0.30–0.86) favoring
EP. Overall survival results favored EP regardless of type
of prior BM therapy [for surgery, patients randomized to
EP had a median OS of 13.5 months compared to
3.2 months for TPC (HR 0.38); for radiotherapy, 10.0 and
5.1 months, respectively (HR 0.56)] or tumor subtype
[HER2-positive, 16.1 vs. 8.6 months (HR 0.55); TNBC,
6.7 vs. 3.8 months (HR 0.27); and hormone receptor-pos-
itive, 12.2 vs. 5.2 months (HR 0.47)].
Considerable improvements in 6- and 12-month survival
rates were also associated with EP treatment. The 6-month
rates were 72.2 and 45.2% for EP and TPC, respectively;
corresponding 12-month rates were 44.4 and 19.4%,
respectively. Forest plot of HRs, with corresponding 95%
CIs and P value, for OS in preselected prognostic factors is
shown in Fig. 2. As depicted, there was consistency of
benefit across all subgroups favoring EP treatment. In those
patients with radiologically detectable but stable and trea-
ted BM on baseline imaging, median OS was 13.2 months
for EP (n = 19) versus 5.8 months for TPC (n = 18) (HR
0.45; 95% CI 0.22–0.92) (Fig. 1). The proportion of
patients alive at 6 and 12 months were 89.5 versus 50%,
and 57.9 versus 22.2% for the EP and TPC arms, respec-
tively. The median PFS was 3.1 months for EP and
2.7 months for TPC (HR 0.84; 95% CI 0.49–1.43;
P = 0.52) (Fig. 1). PFS rates at 3 months were similar
between arms at 50%; 6-month PFS was 28.6 and 19.5% in
the EP and TPC arms, respectively (Table 2).
All BCBM patients had at least one extra-cranial site of
metastasis at baseline: 66% had liver metastases and 72%
had 3 or more sites of metastatic disease. Among BCBM
patients who had measurable systemic disease at baseline
(EP, n = 32; TPC, n = 27), 5 (15.6%) had a systemic
ORR in the EP arm compared with 1 (3.7%) patient in TPC
group (Table 2); all were partial responses. No intra-cranial
responses were seen. Of the remaining patients, approxi-
mately one-third in each arm had stable disease. For the
five patients with a response in the EP arm, median
response duration was 5.6 months; response duration in the
single responder in the TPC group was 3.7 months.
332 Breast Cancer Res Treat (2017) 165:329–341
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Table 1 Demographics and baseline patient characteristics
BMH ITT
Etirinotecan pegol (n = 36) TPC (n = 31) Total (n = 852)
Demographics
Age (years), median 54.5 54.0 55.0
Range 28–75 37–76 28–84
ECOG PS, baseline
0 11 (30.6%) 5 (16.1%) 309 (36.3%)
1 25 (69.4%) 25 (80.6%) 537 (63.0%)
2 0 1 (3.2%) 5 (0.6%)
3 0 0 1 (0.1%)
Cancer history
Time since BC diagnosis (years), median 4.4 5.2 5.6
Time since LR/MBC diagnosis (years), median 2.6 2.4 2.5
Initial disease-free interval (years), median 2.3 3.1 2.7
Time since brain metastases diagnosis (years) 0.91 0.58 NA
Visceral disease at enrollment 30 (83.3%) 27 (87.1%) 643 (75.5%)
Metastatic involvement at study entry
Bones 27 (75.0%) 13 (41.9%) 489 (57.4%)
Brain 19 (52.8%) 18 (58.1%) 37 (4.3%)
Liver 26 (72.2%) 18 (58.1%) 456 (53.5%)
Lung 15 (41.7%) 15 (48.4%) 323 (37.9%)
Hormone receptor status
Positive (ER? or PR?) 25 (69.4%) 21 (67.7%) 585 (68.7%)
Negative 11 (30.6%) 10 (32.3%) 266 (31.2%)
HER2/neu receptor status
Positive 4 (11.1%) 5 (16.1%) 62 (7.3%)
Negative 32 (88.9%) 26 (83.9%) 782 (91.8%)
Triple negative 10 (27.8%) 8 (25.8%) 236 (27.7%)
Prior therapy
Number of prior regimens for MBC, median 3.0 3.0 3.0
Anthracycline
Refractorya
34 (94.4%)
6 (16.7%)
30 (96.8%)
3 (9.7%)
816 (95.8%)
115 (13.5%)
Taxane
Refractorya
36 (100.0%)
18 (50.0%)
31 (100.0%)
13 (41.9%)
852 (100.0%)
343 (40.3%)
Capecitabine
Refractorya
36 (100.0%)
26 (72.2%)
31 (100.0%)
19 (61.3%)
852 (100.0%)
624 (73.2%)
Eribulin 7 (19.4%) 9 (29.0%) 143 (16.8%)
Hormonal therapy 25 (69.4%) 19 (61.3%) 609 (71.5%)
HER2-directed therapiesb 6 (16.7%) 5 (16.1%) 87 (10.2%)
Prior RT to brain 34 (94.4%) 27 (87.0%)
Etirinotecan pegol TPC
BMH (n = 34) ITT (n = 425) BMH (n = 27) ITT (n = 406)
Drug exposure
Therapy received in TPC
Eribulin 8 (29.6%) 164 (40.4%)
Vinorelbine 5 (18.5%) 94 (23.2%)
Gemcitabine 9 (33.3%) 71 (17.5%)
nab-Paclitaxel 3 (11.1%) 31 (7.6%)
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Graded prognostic assessment index
The treatment groups were well balanced for GPA indices
(KPS, tumor subtype, and age) at baseline. Of the 67
patients, 23 had low (0–2; i.e., poorer prognosis) GPA
scores and 44 had higher (2.5–4; i.e., better prognosis)
scores. Thirty-six percent of patients in the EP arm had low
GPA scores versus 32% for the TPC arm; both mean and
median GPA scores for the treatment groups were the same
(mean 2.3, median 2.5; Table 1). The median OS for
patients with a GPA of 0–2 was 7.8 months in the EP arm
and 3.8 months in the TPC arm (HR 0.27;95% CI
0.10–0.72; P\ 0.01) (Table 2). The median OS for
patients with a GPA of 2.5–4 was 13.2 months for EP and
6.9 months for TPC (HR 0.54; 95% CI 0.28–1.04;
P = 0.062). The HR for OS of the 67 patients after
adjusting for the two GPA groups was 0.44, favoring EP.
The same analyses were conducted for patients who had
radiologically detectable but stable BM on baseline imag-
ing. In this smaller group (EP, n = 19; TPC, n = 18), the
same trend was seen. The median OS for patients with a
GPA of 0–2 was 9.6 months for EP and 3.5 months for
TPC; median OS for patients with a GPA of 2.5–4.0 was
16.8 and 6.9 months, respectively.
Safety
Sixty-one patients comprised the safety population, 34 in
the EP arm and 27 in the TPC arm (2 and 4 patients,
respectively, were randomized but did not proceed to
treatment due to withdrawal of consent or rapid deterio-
ration of PS). The proportion of patients who experienced
at least one grade 3 or higher treatment-emergent AE was
lower in the EP arm compared with TPC (50% vs. 70.4%,
respectively; Table 3). Neutropenia, the most common
grade C3 AE, occurred in 33.3% of TPC patients versus
14.7% EP patients. The incidence of grade 3 diarrhea was
nearly identical in the two study arms, 5.9 versus 3.7% in
the EP and TPC arms, respectively. Treatment discontin-
uation was attributed to an AE in seven patients in the EP
arm (neutropenia or neutrophil count, n = 3; diarrhea,
n = 2; ascites, n = 1; and vomiting, n = 1) and 1 patient
in the TPC arm (confusional state, n = 1).
In the BEACON ITT population, a longitudinal analysis
using repeated measure linear mixed model in change from
baseline over 32 weeks showed that EP was statistically
superior (P\ 0.02) in the treatment difference for global
health status and physical functioning and numerically
superior in all other functions. The mean difference
between treatment groups was larger in the BCBM
patients, although the sample size was too small to detect
statistical significance (P[ 0.05).
Post-study treatment
In the BCBM subgroup, 72.2% of those randomized to EP
received at least one subsequent cancer therapy versus
48.4% randomized to TPC. Eribulin and gemcitabine were
Table 1 continued
Etirinotecan pegol TPC
BMH (n = 34) ITT (n = 425) BMH (n = 27) ITT (n = 406)
Paclitaxel 0 18 (4.4%)
Ixabepilone 1 (3.7%) 15 (3.7%)
Docetaxel 1 (3.7%) 13 (3.2%)
Exposure duration (days), median (range) 47.5 (1–540) 48 (1–766) 44 (1–376) 56.5 (1–607)
Number of cycles completed, median (range) 3 (1–23) 3 (1–35) 3 (1–13) 3 (1–26)
BMH
Etirinotecan pegol (n = 36) TPC (n = 31) Total (n = 67)
Graded prognostic assessment (GPA) index
Score
0–2 13 (36.1%) 10 (32.3%) 23 (34.3%)
2.5–4 23 (63.9%) 21 (67.7%) 44 (65.7%)
Median/mean score 2.3/2.5 2.3/2.5 2.3/2.5
BC breast cancer, BMH history of treated, stable breast cancer brain metastases, ECOG Eastern Cooperative Oncology Group, ER estrogen
receptor, GPA graded prognostic assessment, HER2 human epidermal receptor type 2, ITT intention-to-treat, LR locally recurrent, MBC
metastatic breast cancer, PR progestin receptor, PS performance status, RT radiation therapy, TPC treatment of physician’s choice
a Defined as disease progression while receiving therapy in the metastatic setting within 8 weeks of the last dose of the last regimen
b Included trastuzumab, lapatinib, pertuzumab, and TDM1
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Table 2 Efficacy
Etirinotecan pegol (n = 36) TPC (n = 31) P-value
BMH subgroup
Objective response rate (systemic) 5 (15.6%) 1 (3.7%) 0.20
Evaluable populationa n = 32 n = 27
95% CI 5.3–32.8 0.1–19.0
Complete response 0 0
Partial response 5 (15.6%) 1 (3.7%)
Stable disease 9 (28.1%) 9 (33.3%)
Progressive disease 14 (43.8%) 9 (33.3%)
Not evaluable 4 (12.5%) 8 (29.6%)
Overall survival (months)
Median 10.0 4.8 \0.01
95% CI 7.8–15.7 3.7–7.3
6-month OS rate 72.2% 45.2%
12-month OS rate 44.4% 19.4%
Progression-free survival (months)
Median 3.1 2.7 0.52
95% CI 1.8–4.0 1.8–3.7
3-month PFS rate 50.1% 50.0%
6-month PFS rate 28.6% 19.5%
Etirinotecan pegol (n = 19) TPC (n = 18) P-value
Radiologically detectable brain lesions at study entry
Objective response rate (systemic) 4 (25%) 1 (6.3%) 0.33
Evaluable populationa n = 16 n = 16
95% CI 7.3–52.4 0.2–30.2
Complete response 0 0
Partial response 4 (25.0%) 1 (6.3%)
Stable disease 5 (31.3%) 6 (37.5%)
Progressive disease 6 (37.5%) 4 (25.0%)
Not evaluable 1 (6.3%) 5 (31.3%)
Progressive disease in brain lesion 6 (37.5%) 6 (37.5%)
Overall survival (months)
Median 13.2 5.8 0.02
95% CI 8.6–19.6 3.5–8.6
6-month survival rate 89.5% 50.0%
12-month survival rate 57.9% 22.2%
OS by GPA category—BMH Subgroup Etirinotecan pegol (n = 36) TPC (n = 31) P-value
0–2
n 13 10
Median, months 7.8 3.8 \0.01
2.5–4
n 23 21
Median, months 13.2 6.9 0.06
OS by GPA category—radiologically detectable brain lesions at baseline Etirinotecan pegol (n = 19) TPC (n = 18) P-value
0–2
n 6 5
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the most commonly prescribed follow-on therapies in
patients randomized to EP (41.7 and 27.8%, respectively);
the most commonly prescribed subsequent therapies in the
TPC arm were paclitaxel (12.9%) and cyclophosphamide
(12.9%). Use of eribulin (combining those patients who
had received eribulin prior to study, as part of the TPC
group or as follow-on therapy) was similar between the two
groups. For the EP group, 7 (19.4%) patients received
eribulin prior to study and 15 (41.7%) patients as a follow-
on therapy. For the TPC group, 9 (29.0%) patients received
prior eribulin; 8 (25.8%) patients had eribulin as their TPC
agent, and 2 (6.5%) as follow-on therapy.
Discussion
In the overall BEACON study, EP was associated with a
2.1-month improvement in OS compared to TPC; however,
statistical significance was not reached (HR 0.87; 95% CI
0.75, 1.02; P = 0.08) [24]. In a preplanned subgroup
analysis of patients with a history of stable, treated BM, EP
demonstrated a substantial reduction in the risk of death
(HR 0.51) compared to conventional chemotherapy. Med-
ian survival was improved by 5.2 months (10.0 vs.
4.8 months), with a doubling of 12-month survival rate (44
vs. 20%). Findings were even more pronounced in the
small subset of patients with radiologically detectable, but
stable, brain lesions at baseline, with a 7.4-month survival
advantage for those patients receiving EP.
In a post hoc evaluation using the GPA Index as
described herein, treatment with EP was associated with
improved OS for patients in both better and worse prog-
nosis groups, reinforcing the activity of EP in BCBM
patients. The GPA tool, which assigns scores for significant
prognostic indices of KPS, tumor subtype, and age, was
originally developed to predict prognosis in patients with
newly diagnosed BM [25, 26]. It should be noted that many
of the BCBM patients in this analysis were not newly
diagnosed with BM; however, the GPA analysis provided a
way to stratify patients to correct for potential imbalances
between the groups, most notably the differences in HER2
and performance status.
All BCBM patents randomized into BEACON had
extra-cranial disease, the majority of whom (72%) had a
high burden of systemic disease (defined as three or more
sites of metastases). This is consistent with the rarity of
CNS lesions being the solitary site of disease in MBC,
occurring in fewer than 5% [28]. Most BCBM patients die
from progression of systemic (extra-cranial) disease or a
combination of extra-cranial and intra-cranial progression.
In one series of 83 patients with BCBM, only 15% died of
isolated CNS disease progression with stable systemic
disease at the time of death [29]. Hence, control of both
intra-cranial and extra-cranial disease is crucial. No intra-
cranial objective responses were seen in BCBM patients
randomized to either EP or TPC; however, two patients in
the EP arm had non-target CNS lesions (present at base-
line) become absent during their course of treatment. Of
note, BCBM patients in the BEACON study were required
to have had all CNS lesions treated (with either radio-
therapy or surgery) and no evidence of radiographic pro-
gression or neurological symptoms prior to randomization.
As such, all brain lesions present at study entry were
considered non-target lesions by RECIST and best overall
‘‘in-brain response’’ could therefore be a complete
response, ‘‘non-CR, non-PD,’’ or progression. The ongoing
phase three trial in BCBM patients (ClinicalTrials.gov
NCT02915744) uses the more recently introduced RANO-
BR criteria [30], which assesses intra-cranial and extra-
cranial disease independently for both response and
progression.
Unselected, retrospective, historical data indicate that
median survival of patients with brain metastases from
breast cancer after radiation therapy is approximately
4–6 months [31–33], and varies depending on prognostic
factors from 3.4 months to 2 years [25, 26]. We
acknowledge that the results reported herein are in a highly
selected patient population and that the lack of systematic
brain assessment is a limitation of the study (head imaging
was only required at baseline and follow-up for patients
with focal neurological deficits or a known history of brain
metastases). However, as a recent review of the literature
emphasizes, there is a relative paucity of data in this patient
population, with only small prospective trials evaluating
Table 2 continued
OS by GPA category—radiologically detectable brain lesions at baseline Etirinotecan pegol (n = 19) TPC (n = 18) P-value
Median, months 9.6 3.5
2.5–4
n 13 13
Median, months 16.8 6.9
a Efficacy evaluable population (measureable systemic disease at baseline required)
BMH history of treated, stable breast cancer brain metastases, CI confidence interval, GPA graded prognostic assessment, OS overall survival,
PFS progression-free survival, SD stable disease, TPC treatment of physician’s choice
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Fig. 1 Kaplan–Meier estimates
for a overall survival and
b progression-free survival for
patients with stable, treated
brain metastases; and c overall
survival for patients with
radiologically detectable, but
stable, brain lesions at study
entry. CI confidence interval,
HR hazard ratio, mOS median
overall survival, mPFS median
progression-free survival, TPC
treatment of physician’s choice
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chemotherapy in patients with BCBM previously treated
with either systemic therapy or radiotherapy [11]. The
biological rationale for EP accumulation in brain metas-
tases is strong, with results of this study providing solid
hypothesis generation. The activity of single-agent EP
against intra-cranial malignancies is supported by a phase 2
trial in which 3 of 18 patients with glioblastoma multi-
forme (GBM) progressing after bevacizumab treatment had
confirmed partial responses according to RANO criteria,
corresponding to a 17% response rate; two of the responses
were highly durable, lasting C19 months [34]. To place
this in context, it is rare to see objective responses in
Table 3 Common grade 3 or higher adverse events
Etirinotecan pegol TPC
BMH (n = 34) ITT (n = 425) BMH (n = 27) ITT (n = 406)
Number of patients with at least one AE grade 3 or higher 17 (50.0%) 204 (48.0%) 19 (70.4%) 256 (63.1%)
Hematologic
Neutropenia-related events 5 (14.7%) 41 (9.6%) 9 (33.3%) 125 (30.8%)b
Anemia 1 (2.9%)a 20 (4.7%)a 1 (3.7%) 19 (4.7%)
Non-hematologic
Diarrhea 2 (5.9%)a 41 (9.6%)a 1 (3.7%)a 5 (1.2%)a
Nausea 2 (5.9%)a 15 (3.5%)a 0 8 (2.0%)a
Pleural effusion 2 (5.9%) 15 (3.5%) 0 16 (3.9%)
Dehydration 1 (2.9%)a 17 (3.5%)a 1 (3.7%)b 8 (2.0%)b
Hypokalemia 1 (2.9%) 10 (2.4%) 1 (3.7%) 7 (2.0%)
Hyponatremia 0 3 (\1%)a 2 (7.4%) 8 (2.0%)
Neuropathy-related events 0 2 (\1%) 0 15 (3.7%)a
AE adverse event, BMH history of treated, stable breast cancer brain metastases, ITT intention-to-treat, TPC treatment of physician’s choice
a No grade 4 reported
b Grade 5 event(s) reported
Fig. 2 Forest plot of hazard ratios (HR) with 95% confidence
intervals (CI) for overall survival for selected prognostic factors in the
intention-to-treat (ITT) population with a history of treated,
stable brain metastases. BC breast cancer, CI confidence interval,
ECOG Eastern Cooperative Oncology Group, HER2 human epider-
mal growth factor receptor 2, HR hazard ratio, TPC treatment of
physician’s choice
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patients with GBM whose disease has progressed on
bevacizumab as evidenced by phase II trials [35–47]. The
plausibility of an enhanced survival effect using EP is
further strengthened by the non-clinical pharmacology data
in mouse models of human tumors including the CNS,
comparing EP to either conventional irinotecan or to the
TPC agents used in BEACON. The data from two separate
studies support differential distribution and markedly
longer retention of EP and SN38 active metabolite, with
resultant longer survival in mice treated with EP, 100-fold
higher brain concentrations and resolution of brain lesions
upon necropsy [22, 23].
As a topoisomerase-I inhibitor, SN38 derived from EP
has a mechanism of action and a toxicity spectrum that is
distinct from that of the tubulin-inhibitor cytotoxic drugs,
which comprises most of the standard of care chemother-
apies for MBC treatment. In patients with advanced
malignancies who have received multiple prior regimens,
an alternative mechanism of action is important: it reduces
the likelihood of cross-resistance and contribution to
cumulative toxicities. In the BEACON trial [24, 48] and
the BCBM subgroup, EP demonstrated a lower rate of
grade 3 and dose-limiting/QoL-reducing toxicities associ-
ated with tubulin-inhibitors (notably neuropathy, myelo-
suppression, fatigue, cardiomyopathy, and alopecia),
although EP was associated with more gastrointestinal
toxicities, including diarrhea.
There remains a critical need for therapeutic interven-
tions that prolong patient survival and maintain or improve
QoL of patients with breast cancer and brain metastases.
Despite the relatively small number of patients in this
preplanned subgroup analysis, the clear survival benefit
and favorable safety profile demonstrated over that of
commonly prescribed agents in this setting, together with
phase II evidence of single-agent activity in recurrent high-
grade primary brain tumors, support further study of EP as
treatment of brain metastases for SN38-sensitive primary
tumors including breast cancer. An international phase
three trial in this population is underway (ClinicalTrials.-
gov NCT02915744). Nektar Therapeutics submitted a
marketing authorization application for conditional
approval of EP in Europe for the treatment of adult patients
with breast cancer and brain metastases. The decision
regarding conditional approval is expected in 2017.
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